Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
暂无分享,去创建一个
H. G. van der Poel | T. Scheenen | J. Witjes | J. Barentsz | A. Bergman | M. Janssen | M. Gotthardt | Marianne A. Jonker | P. Zamecnik | W. Noordzij | W. Vogel | I. V. van Oort | N. Mehra | W. Gerritsen | J. Nagarajah | D. Oprea-Lager | A. Vis | W. van Gemert | M. de Groot | B. Privé | H. Westdorp | C. Muselaers | J. Verzijlbergen | Constantijn H. J. Muselaers | Constantijn H. J. Muselaers | Michel de Groot | P. Zámecnik
[1] J. Witjes,et al. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer , 2021, Prostate cancer and prostatic diseases.
[2] Steffie M. B. Peters,et al. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[3] T. Scheenen,et al. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients , 2021, The Journal of Nuclear Medicine.
[4] Henk G van der Poel,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.
[5] J. Witjes,et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology , 2020, Prostate Cancer and Prostatic Diseases.
[6] H. G. van der Poel,et al. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial , 2020, BMC cancer.
[7] Sean S. Park,et al. Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer , 2020, International journal of radiation oncology, biology, physics.
[8] G. Ploussard. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. , 2020, European urology.
[9] Steffie M. B. Peters,et al. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study , 2020, Clinical Cancer Research.
[10] Ash A. Alizadeh,et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.
[11] E. Goetghebeur,et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. , 2020 .
[12] T. Derlin,et al. Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[13] D. Murphy,et al. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.
[14] L. Collette,et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. , 2018, The Lancet. Oncology.
[15] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[16] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Publisher's Note , 2018, Anaesthesia.
[18] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.
[19] K. Pienta,et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.
[20] S. Daneshmand,et al. Androgen deprivation therapy: evidence‐based management of side effects , 2013, BJU international.
[21] J. Eastham,et al. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer , 2009, Prostate Cancer and Prostatic Diseases.
[22] A. D'Amico,et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Wheldon,et al. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.